Implementable Deep Learning for Multi‐sequence Proton MRI Lung Segmentation: A Multi‐center, Multi‐vendor, and Multi‐disease Study

Author:

Astley Joshua R.12ORCID,Biancardi Alberto M.1,Hughes Paul J. C.1ORCID,Marshall Helen1ORCID,Collier Guilhem J.1,Chan Ho‐Fung1ORCID,Saunders Laura C.1ORCID,Smith Laurie J.1,Brook Martin L.1,Thompson Roger3ORCID,Rowland‐Jones Sarah3,Skeoch Sarah45,Bianchi Stephen M.3,Hatton Matthew Q.3,Rahman Najib M.6,Ho Ling‐Pei7,Brightling Chris E.8,Wain Louise V.89,Singapuri Amisha8,Evans Rachael A.10,Moss Alastair J.811,McCann Gerry P.811,Neubauer Stefan6,Raman Betty6ORCID,Wild Jim M.112ORCID,Tahir Bilal A.1212ORCID,

Affiliation:

1. POLARIS, Department of Infection, Immunity & Cardiovascular Disease The University of Sheffield Sheffield UK

2. Department of Oncology and Metabolism The University of Sheffield Sheffield UK

3. Sheffield Teaching Hospitals NHS Foundation Trust Sheffield UK

4. Royal National Hospital for Rheumatic Diseases Royal United Hospital NHS Foundation Trust Bath UK

5. Arthritis Research UK Centre for Epidemiology, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health University of Manchester, Manchester Academic Health Sciences Centre Manchester UK

6. Division of Cardiovascular Medicine, Radcliffe Department of Medicine, National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC) University of Oxford Oxford UK

7. MRC Human Immunology Unit University of Oxford Oxford UK

8. The Institute for Lung Health, NIHR Leicester Biomedical Research Centre University of Leicester Leicester UK

9. Department of Health sciences University of Leicester Leicester UK

10. University Hospitals of Leicester NHS Trust University of Leicester Leicester UK

11. Department of Cardiovascular Sciences University of Leicester Leicester UK

12. Insigneo Institute for In Silico Medicine The University of Sheffield Sheffield UK

Abstract

BackgroundRecently, deep learning via convolutional neural networks (CNNs) has largely superseded conventional methods for proton (1H)‐MRI lung segmentation. However, previous deep learning studies have utilized single‐center data and limited acquisition parameters.PurposeDevelop a generalizable CNN for lung segmentation in 1H‐MRI, robust to pathology, acquisition protocol, vendor, and center.Study typeRetrospective.PopulationA total of 809 1H‐MRI scans from 258 participants with various pulmonary pathologies (median age (range): 57 (6–85); 42% females) and 31 healthy participants (median age (range): 34 (23–76); 34% females) that were split into training (593 scans (74%); 157 participants (55%)), testing (50 scans (6%); 50 participants (17%)) and external validation (164 scans (20%); 82 participants (28%)) sets.Field Strength/Sequence1.5‐T and 3‐T/3D spoiled‐gradient recalled and ultrashort echo‐time 1H‐MRI.Assessment2D and 3D CNNs, trained on single‐center, multi‐sequence data, and the conventional spatial fuzzy c‐means (SFCM) method were compared to manually delineated expert segmentations. Each method was validated on external data originating from several centers. Dice similarity coefficient (DSC), average boundary Hausdorff distance (Average HD), and relative error (XOR) metrics to assess segmentation performance.Statistical TestsKruskal–Wallis tests assessed significances of differences between acquisitions in the testing set. Friedman tests with post hoc multiple comparisons assessed differences between the 2D CNN, 3D CNN, and SFCM. Bland–Altman analyses assessed agreement with manually derived lung volumes. A P value of <0.05 was considered statistically significant.ResultsThe 3D CNN significantly outperformed its 2D analog and SFCM, yielding a median (range) DSC of 0.961 (0.880–0.987), Average HD of 1.63 mm (0.65–5.45) and XOR of 0.079 (0.025–0.240) on the testing set and a DSC of 0.973 (0.866–0.987), Average HD of 1.11 mm (0.47–8.13) and XOR of 0.054 (0.026–0.255) on external validation data.Data ConclusionThe 3D CNN generated accurate 1H‐MRI lung segmentations on a heterogenous dataset, demonstrating robustness to disease pathology, sequence, vendor, and center.Evidence Level4.Technical EfficacyStage 1.

Funder

BHF Centre of Research Excellence, Oxford

Medical Research Council

Yorkshire Cancer Research

Publisher

Wiley

Subject

Radiology, Nuclear Medicine and imaging

Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3